The trial numbers are undisclosed. The stock is up 91 percent.

On Wednesday morning, an investigational cancer treatment entered two systems at once.

The medical system received an interim announcement. It was told that a Phase 3 trial had met its primary recurrence-free-survival endpoint and a secondary endpoint concerning distant metastasis. It was not given the specific Phase 3 recurrence rates, survival rates, or detailed safety results. Overall-survival follow-up continues. The treatment is not approved.

The market system received the same announcement and produced the number 91.

That was the reported rise in Moderna shares, to $120, in premarket trading.

Human beings are forever being told to wait for the data. Money has apparently been excused from this requirement on account of an early appointment.

The treatment is called intismeran autogene. It is a personalized mRNA therapy developed by Moderna and studied with Merck’s Keytruda after surgery for cutaneous melanoma. In the Phase 3 trial, 1,137 people were assigned two to one to receive the combination or Keytruda alone for roughly a year.

The companies said the combination met the trial’s recurrence-free-survival endpoint. One report also said it met the distant-metastasis-free-survival endpoint. Those are meaningful company-reported findings from a prespecified interim analysis. They are not the missing effect sizes, an approval decision, or evidence that anyone has been cured.

The distinction is not a cold shower administered to hope. It is the plumbing that keeps hope from being sold as a finished appliance.

The phrase “cancer vaccine” requires similar maintenance.

On this planet, people usually meet the word vaccine before they meet the word melanoma. They may reasonably imagine a preventive shot given to healthy people so they do not develop cancer. This is not that. Intismeran is a patient-specific therapeutic approach studied after a person’s melanoma was surgically removed, alongside an approved treatment. It is intended to help the immune system recognize features of that person’s tumor.

Moderna’s chief executive described the idea as teaching the immune system about mutations it had missed. This is a striking way to explain personalized treatment. It makes the body a classroom, the tumor a lesson, and mRNA the substitute teacher arriving with a very specific folder.

The folder is not yet available at the pharmacy.

Intismeran remains investigational. The companies plan to take the Phase 3 data into discussions with regulators about possible approval filings. A discussion is not a filing. A filing is not approval. Approval is not availability everywhere to everyone who might benefit. Modern medicine has many doors, and a company announcement is permitted to stand near the first one looking photogenic.

The coverage divided itself according to the old civic arrangement.

One account looked inward, toward tumor mutations, immune recognition, the trial population, and the possibility of a new personalized treatment. It called the results promising while preserving important boundaries: no disclosed Phase 3 rates and no approved product.

Another looked outward, toward Moderna’s 91% premarket rise, analyst reactions, potential sales, the decline of the company’s COVID-vaccine business, and Merck’s eventual loss of Keytruda exclusivity. It also included the absent numbers and the regulatory boundary. But it led with the one result that had already been fully quantified.

Both frames contain facts. They simply answer different questions.

The medical frame asks what happened to people in the trial.

The market frame asks what happened to the stock after the announcement.

The first answer has not been released in numerical detail. The second answer arrived to the nearest percentage point.

This is how an investigational result becomes two kinds of promise before lunch.

For patients and families living with the possibility of melanoma returning, the missing clinical numbers are not clerical decorations. They are part of the answer. How large was the difference between the groups? How durable will it be? What were the adverse events? What will continued overall-survival follow-up show? The reports available here do not provide those answers.

That uncertainty belongs to medicine, not to the patients. They did not design the announcement, choose the headlines, or ring the imaginary premarket bell. They are owed precision because the subject is their lives.

The market owes nobody patience. It is a mechanism for converting expectation into price, often before expectation has found its shoes.

Analysts called the timing surprisingly positive and the update a clear positive for Moderna shares and its business. They were speaking their native language. Analysts are not employed to sit beside an undisclosed table and whisper that its columns may contain sorrow, relief, ambiguity, and confidence intervals. They are employed to decide what an announcement may be worth while the announcement is still warm.

The resulting number, 91%, is therefore precise in a way the underlying medical story is not yet precise in public.

It does not tell us that recurrence fell by 91%. It does not tell us that survival improved by 91%. It does not tell us that the treatment is 91% effective, 91% likely to be approved, or 91% likely to help any particular person. It tells us that Moderna shares rose 91% in Wednesday premarket trading after the news.

That is a market event. It is not a clinical endpoint wearing a tie.

Yet headlines place these measurements close together, where they begin socializing without supervision. “Phase 3 goal” stands beside “stock nearly doubles.” “Cancer vaccine” stands beside “promising.” The reader is left to keep treatment separate from prevention, endpoints separate from effect sizes, company reporting separate from regulatory judgment, and share appreciation separate from patient benefit.

This is a great deal of unpaid sorting for a person who merely opened the news.

The companies may eventually disclose results that justify the medical excitement. Regulators may eventually review an application. The therapy may eventually become an important treatment. None of those possibilities needs to be mocked, and none has to be converted into a present fact to be taken seriously.

Hope can survive a sentence containing the word investigational.

What hope cannot survive forever is being asked to serve simultaneously as a clinical conclusion, a business forecast, and a graphic element beneath a rising arrow.

For now, the public record described in these reports contains a Phase 3 endpoint announcement without the specific Phase 3 outcome numbers. It contains an unapproved personalized treatment studied after melanoma surgery. It contains plans for regulatory discussions. It contains ongoing overall-survival follow-up.

And it contains a 91% premarket rise.

The medical story is waiting for the table.

The financial story has already printed the receipt.